Related Experiment Video
Updated: Dec 20, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer
Lior Rosenfeld1, Amiram Sananes1, Yuval Zur1
1Avram and Stella Goldstein-Goren Department of Biotechnology Engineering and the National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Abstract:
The repertoire of methods for the detection and chemotherapeutic treatment of prostate cancer (PCa) is currently limited. Prostate-specific membrane antigen (PSMA) is overexpressed in PCa tumors and can be exploited for both imaging and drug delivery. We developed and characterized four nanobodies that present tight and specific binding and internalization into PSMA+ cells and that accumulate specifically in PSMA+ tumors. We then conjugated one of these nanobodies to the cytotoxic drug doxorubicin, and we show that the conjugate internalizes specifically into PSMA+ cells, where the drug is released and induces cytotoxic activity. In vivo studies show that the extent of tumor growth inhibition is similar when mice are treated with commercial doxorubicin and with a 42-fold lower amount of the nanobody-conjugated doxorubicin, attesting to the efficacy of the conjugated drug. These data highlight nanobodies as promising agents for the imaging of PCa tumors and for the targeted delivery of chemotherapeutic drugs.
Insights
Researchers developed nanobodies targeting prostate cancer (PCa) cells. These nanobodies deliver chemotherapy drugs like doxorubicin effectively, significantly inhibiting tumor growth with lower doses for improved PCa treatment.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Current prostate cancer (PCa) detection and treatment methods are limited.
- Prostate-specific membrane antigen (PSMA) is highly expressed in PCa, offering a target for imaging and therapy.
Purpose of the Study:
- To develop and characterize nanobodies for PSMA-targeted imaging and drug delivery in PCa.
- To evaluate the efficacy of a nanobody-doxorubicin conjugate for PCa treatment.
Main Methods:
- Developed and characterized four nanobodies with high affinity and specificity for PSMA.
- Conjugated a nanobody to doxorubicin and assessed its internalization and cytotoxicity in PSMA+ cells.
- Evaluated the in vivo efficacy of the nanobody-doxorubicin conjugate in mice models.
Main Results:
- Nanobodies showed specific binding and internalization into PSMA+ cells and accumulated in PSMA+ tumors.
- The nanobody-doxorubicin conjugate demonstrated specific internalization and potent cytotoxic activity in PSMA+ cells.
- In vivo studies revealed significant tumor growth inhibition with a 42-fold lower dose of the conjugate compared to free doxorubicin.
Conclusions:
- Nanobodies are effective agents for targeted prostate cancer imaging.
- Nanobody-drug conjugates represent a promising strategy for targeted chemotherapy delivery in PCa, enhancing efficacy and reducing dosage.
